MRI enhanced features, pathology and prognosis of intrahepatic mass-forming cholangiocarcinoma

Share this content in WeChat

• Clinical Article •

WEI Youping ZHANG Shun SONG Meina WU Wei ZHANG Lihong

WEI Y P, ZHANG S, SONG M N, et al. MRI enhanced features, pathology and prognosis of intrahepatic mass-forming cholangiocarcinoma[J]. Chin J Magn Reson Imaging, 2023, 14(8): 68-72. DOI:10.12015/issn.1674-8034.2023.08.011.

Abstract

[Abstract] Objective To explore the relationship between MRI enhanced features, pathological basis and prognosis of intrahepatic mass-forming cholangiocarcinoma (IMCC).Materials and Methods The data of intrahepatic cholangiocarcinoma (ICC) patients admitted to Aviation General Hospital of China Medical University from January 2008 to June 2020 were retrospectively analyzed. A total of 69 cases of IMCC were included in the study including 62 males and 7 females. According to the different MRI enhancement methods of IMCC, they were divided into 3 groups: progressive enhancement group (25 cases), peripheral enhancement group (24 cases) and rich blood supply group (20 cases). The MRI findings and pathological characteristics of the three groups were analyzed, and the survival rate of the three groups was compared.Results The enhancement degree of MRI was related to the proportion of tumor cells, fibrous tissues, and other tissues ( such as mucus and tissue necrosis). The median survival time of all patients was 35.9 months (95% CI: 17.4-54.6), the 1-year cumulative survival rate was 75.9%, the 3-year cumulative survival rate was 46.7%, and the 5-year cumulative survival rate was 23.4%. The 1-year, 3-year, and 5-year survival rates of patients in progressive enhancement group were 75.0%, 41.3%, and 20.6%, those in peripheral enhancement group were 71.8%, 47.9%, and 18.0%, and those in rich blood supply group were 83.3%, 51.3%, and 32.1%, respectively. Log rank test showed that there was no significant difference in survival rate among the three groups (χ²=1.117, P=0.572). There was no significant difference in 1-year survival rate among the three groups (F=0.50, P=0.616), and no significant difference in 3-year survival rate (F=0.632, P=0.725). There was a significant difference in 5-year survival rate (F=5.93, P=0.007). The rich blood supply group was superior to the progressive reinforcement group (P=0.013) and the peripheral reinforcement group (P=0.001).Conclusions Different enhancement modes of MRI in IMCC have their corresponding pathological basis. There may be a correlation between different reinforcement methods and prognosis, and blood supply rich ICC may have an advantage in 5-year survival rate.

[Keywords] liver tumor；intrahepatic cholangiocarcinoma；pathology；prognosis；magnetic resonance imaging

Contributor Information

WEI Youping¹ ZHANG Shun¹ SONG Meina¹ WU Wei² ZHANG Lihong^2*

¹ Department of imaging, Aviation General Hospital, China Medical University, Beijing 100012, China

² Department of hepatobiliary surgery, Affiliated Hospital of Yangzhou University, Beijing 225012, China

Corresponding author: Zhang LH, E-mail: zhanglh@yzu.edu.cn

Conflicts of interest None.

Publication Information

ACKNOWLEDGMENTS National Natural Science Foundation of China (No. 82001964).

Received 2022-10-17

Accepted 2023-07-27

DOI: 10.12015/issn.1674-8034.2023.08.011

Text

References

[1]

BERTUCCIO P, MALVEZZI M, CARIOLI G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma[J]. J Hepatol, 2019, 71(1): 104-114. DOI: 10.1016/j.jhep.2019.03.013.

[2]

ZHOU J, SUN H C, WANG Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition)[J]. Liver Cancer, 2018, 7(3): 235-260. DOI: 10.1159/000488035.

[3]

YAMASAKI S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification[J]. J Hepatobiliary Pancreat Surg, 2003, 10(4): 288-291. DOI: 10.1007/s00534-002-0732-8.

[4]

LIM J H. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings[J]. AJR Am J Roentgenol, 2003, 181(3): 819-827. DOI: 10.2214/ajr.181.3.1810819.

[5]

GRAVELY A K, VIBERT E, SAPISOCHIN G. Surgical treatment of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2022, 77(3): 865-867. DOI: 10.1016/j.jhep.2022.01.004.

[6]

WANG N Y, HUANG A, KUANG B H, et al. Progress in radiotherapy for cholangiocarcinoma[J/OL]. Front Oncol, 2022, 12: 868034 [2023-07-01]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.868034/full. DOI: 10.3389/fonc.2022.868034.

[7]

ARGEMI J, PONZ-SARVISE M, SANGRO B. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: current and developing strategies[J]. Adv Cancer Res, 2022, 156: 367-413. DOI: 10.1016/bs.acr.2022.03.002.

[8]

MANZIA T M, PARENTE A, LENCI I, et al. Moving forward in the treatment of cholangiocarcinoma[J]. World J Gastrointest Oncol, 2021, 13(12): 1939-1955. DOI: 10.4251/wjgo.v13.i12.1939.

[9]

KRENZIEN F, NEVERMANN N, KROMBHOLZ A, et al. Treatment of intrahepatic cholangiocarcinoma-a multidisciplinary approach[J/OL]. Cancers, 2022, 14(2): 362 [2023-07-01]. https://www.mdpi.com/2072-6694/14/2/362. DOI: 10.3390/cancers14020362.

[10]

BANALES J M, MARIN J J G, LAMARCA A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(9): 557-588. DOI: 10.1038/s41575-020-0310-z.

[11]

CHEN Y F, LIU H Z, ZHANG J Y, et al. Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma: a multicenter study from China[J/OL]. BMC Cancer, 2021, 21(1): 1299 [2023-07-01]. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-09035-5. DOI: 10.1186/s12885-021-09035-5.

[12]

KIM S A, LEE J M, LEE K B, et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at Multiphasic CT, with special emphasis on arterial enhancement pattern: correlation with clinicopathologic findings[J]. Radiology, 2011, 260(1): 148-157. DOI: 10.1148/radiol.11101777.

[13]

SHAN K, LI Zhiyao. Comparison of imaging features of intrahepatic cholangiocarcinoma with different pathological grading[J]. Radiol Pract, 2018, 33(6): 582-586. DOI: 10.13609/j.cnki.1000-0313.2018.06.008.

[14]

LI B R, ZHANG K, ZHOU L X, et al. The value of tumor blood supply characteristics of arterial phase in evaluating the prognosis of patients with intrahepatic mass-forming cholangiocarcinoma[J]. Chin J Radiol, 2020, 54(6): 563-567. DOI: 10.3760/cma.j.cn112149-20190618-00497.

[15]

SEO N, KIM D Y, CHOI J Y. Cross-sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis[J/OL]. AJR Am J Roentgenol, 2017, 209(2): W64-W75 [2023-07-01]. https://www.ajronline.org/doi/10.2214/AJR.16.16923. DOI: 10.2214/AJR.16.16923.

[16]

XING L H, ZHUO L Y, WANG J N, et al. Values of MRI imaging presentations in the hepatobiliary phase, DWI and T2WI sequences in predicting pathological grades of intrahepatic mass-forming cholangiocarcinoma[J/OL]. Front Oncol, 2022, 12: 867702 [2023-07-01]. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.867702/full. DOI: 10.3389/fonc.2022.867702.

[17]

GRANATA V, GRASSI R, FUSCO R, et al. Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features[J]. Radiol Med, 2021, 126(12): 1584-1600. DOI: 10.1007/s11547-021-01428-7.

[18]

GRANATA V, FUSCO R, SETOLA S V, et al. Radiological assessment of secondary biliary tree lesions: an update[J/OL]. J Int Med Res, 2020, 48(6): 300060519850398 [2023-07-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432986/. DOI: 10.1177/0300060519850398.

[19]

YANG Q X, CAI Q, WEN H L, et al. The CT and MRI features of primary intrahepatic lymphoepithelioma-like cholangiocarcinoma[J]. AJR Am J Roentgenol, 2021, 216(2): 393-402. DOI: 10.2214/AJR.20.22937.

[20]

BRAGAZZI M C, RIDOLA L, SAFARIKIA S, et al. New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin[J]. Ann Gastroenterol, 2018, 31(1): 42-55. DOI: 10.20524/aog.2017.0209.

[21]

VIJ M, PURI Y, RAMMOHAN A, et al. Pathological, molecular, and clinical characteristics of cholangiocarcinoma: a comprehensive review[J]. World J Gastrointest Oncol, 2022, 14(3): 607-627. DOI: 10.4251/wjgo.v14.i3.607.

[22]

NAKANUMA Y, SATO Y, HARADA K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept[J]. World J Hepatol, 2010, 2(12): 419-427. DOI: 10.4254/wjh.v2.i12.419.

[23]

FUJITA N, ASAYAMA Y, NISHIE A, et al. Mass-forming intrahepatic cholangiocarcinoma: enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings[J]. Eur Radiol, 2017, 27(2): 498-506. DOI: 10.1007/s00330-016-4386-3.

[24]

JIN K P, SHENG R F, YANG C, et al. Combined arterial and delayed enhancement patterns of MRI assist in prognostic prediction for intrahepatic mass-forming cholangiocarcinoma (IMCC)[J]. Abdom Radiol, 2022, 47(2): 640-650. DOI: 10.1007/s00261-021-03292-5.

[25]

PANETTIERI E, MAKI H, KIM B J, et al. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma[J/OL]. Surg Oncol, 2022, 40: 101696 [2023-07-01]. https://linkinghub.elsevier.com/retrieve/pii/S0960-7404(21)00185-7. DOI: 10.1016/j.suronc.2021.101696.

[26]

NAM J G, LEE J M, JOO I, et al. Intrahepatic mass-forming cholangiocarcinoma: relationship between computed tomography characteristics and histological subtypes[J]. J Comput Assist Tomogr, 2018, 42(3): 340-349. DOI: 10.1097/RCT.0000000000000695.

[27]

MIN J H, KIM Y K, CHOI S Y, et al. Intrahepatic mass-forming cholangiocarcinoma: arterial enhancement patterns at MRI and prognosis[J]. Radiology, 2019, 290(3): 691-699. DOI: 10.1148/radiol.2018181485.

PREV Imaging radiomics features based on DCE-MRI combined with ADC in predicting expression level of Ki-67 in breast cancer

NEXT Microsatellite instability of rectal cancer based on magnetic resonance diffusion kurtosis imaging

LINK

Tel & Fax: +8610-67113815 E-mail: editor@cjmri.cn